Disease-free survival of Ph-positive ALL by status of disease at study entry for those treated with hyper-CVAD and imatinib mesylate. One de novo relapsed after allogeneic SCT (patient no. 7), one CR at start relapsed after change in therapy (patient no. 6), and one primary refractory (patient no. 1) relapsed on therapy without SCT. Deaths in complete remission (one de novo, one primary refractory) are censored.